Takeda Pharm Stock Price, News & Analysis

Takeda and Enel North America have signed a 12-year virtual power purchase agreement (VPPA) to advance Takeda's sustainability goals. The agreement is expected to generate approximately 350,000 Megawatt Hours (MWh) of renewable energy credits annually, covering around 20% of Takeda’s current Scope 1 and 2 GHG emissions. The VPPA facilitates the purchase of electricity from Enel’s 79 MW Seven Cowboy wind project in Oklahoma, ensuring a sustainable energy source for Takeda’s U.S. facilities. This aligns with Takeda's target to reduce GHG emissions by 40% by 2025 and achieve net-zero emissions by 2035.

Takeda announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval for maribavir, a treatment for cytomegalovirus (CMV) in adults post-transplant. This would be the first CMV-specific UL97 protein kinase inhibitor in the EU. The recommendation stems from the Phase 3 SOLSTICE study, which showed maribavir's superiority over conventional therapies at week 8. CMV affects 16%-70% of transplant recipients, necessitating effective treatment options.

Takeda has launched the CDPATH™ program, a personalized prognostic tool designed for Crohn's disease patients in the U.S. This tool predicts the risk of developing serious complications within three years using blood tests, and it's offered at no cost to eligible adult patients. The program aims to facilitate shared decision-making between patients and healthcare providers by integrating patient-specific markers with clinical assessments. CDPATH is available through over 2,500 locations nationwide, enhancing patient-centered care for over three million people affected by inflammatory bowel disease.

Takeda has launched four new partnerships under its Global Corporate Social Responsibility (CSR) Program, contributing a total of JPY 19.7 billion (approximately USD 140.7 million) since its inception in 2016. The new partners include Ipas, Plan International, Pure Earth, and UNFPA, focusing on improving healthcare for marginalized populations in various countries. Notably, funds will aid in enhancing sexual and reproductive health services, combatting gender-based violence, and addressing childhood lead poisoning across Ethiopia, Somalia, Colombia, and more.

Takeda announced that its dengue vaccine, QDENGA (TAK-003), has been approved by the Indonesia National Agency for Drug and Food Control (BPOM) for individuals aged 6 to 45. This makes QDENGA the only dengue vaccine in Indonesia that does not require pre-vaccination testing. The approval marks the first commercialization of QDENGA outside Japan. Dengue poses a significant health threat in Indonesia, with over 63,000 cases and nearly 600 deaths reported in the first half of 2022. Takeda aims to provide this vaccine globally and is also seeking EU regulatory approval.

NextRNA Therapeutics announces the appointment of Dominique Verhelle, PhD, MBA, as CEO, effective immediately. Verhelle, a co-founder of the company, has spearheaded its scientific and corporate strategy since its inception. Under her leadership, NextRNA secured $56M in financing to advance its unique platform aimed at developing small molecule drugs targeting non-coding RNA interactions. Additionally, Jason Katz has been appointed as VP and Head of Drug Discovery, bringing extensive drug discovery experience from IFM Therapeutics and Merck.

Takeda reported its Q1 FY2022 financial results with core revenue growth of +8.3% at constant exchange rates (CER) and a core operating profit growth of +17%. Reported revenues reached 972.5 billion yen, representing a +2.4% rise, while the operating profit was 150.5 billion yen, down -39.4% due to a prior year one-time gain. Key business areas, particularly Growth & Launch Products, saw a significant revenue boost of +26% at CER. Takeda remains on track to meet its FY2022 management guidance amidst a challenging macroeconomic environment.

Takeda announced that its Phase 3 clinical trial, ADVANCE-1, evaluating HYQVIA for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), met its primary endpoint. The treatment reduced relapse rates significantly compared to placebo (9.7% vs 31.4%; p-value = 0.0045). The trial involved 132 adult patients previously on IVIG therapy. Takeda plans to submit regulatory applications in the US and EU for HYQVIA in fiscal year 2022.

Takeda Pharmaceutical Company Limited has submitted its Corporate Governance Report to the Tokyo Stock Exchange, adhering to TSE regulations. This report, rooted in the revised Corporate Governance Code effective as of June 11, 2021, highlights a diverse Board of Directors with a composition of 4 internal and 11 independent external directors. The report emphasizes increased transparency and independence in governance, with advisory committees staffed entirely by external directors. The full report can be accessed on Takeda’s website and the Japan Exchange Group’s platform.